Accenture Ventures announced a strategic investment in QuantHealth, an AI-driven startup specializing in cloud-based clinical trial simulations.
QuantHealth’s platform, leveraging AI algorithms trained on an extensive dataset of 350 million patients and comprehensive biomedical knowledge graphs, empowers pharmaceutical companies to forecast clinical trial outcomes with remarkable precision. It allows for testing numerous trial variations, identifying optimal trial designs, and facilitating key decisions on drug repurposing and trial progression.
Significant challenges hinder the sector of drug development, including the high cost and low success rates of clinical trials. They also often cost billions, with only 10% of drugs reaching the market.
QuantHealth’s simulation platform aims to mitigate these risks, speeding up and refining drug development. The company is already collaborating with global pharmaceutical firms, utilizing its platform in clinical trial design and development.
QuantHealth also joins the Project Spotlight initiative by Accenture Ventures, aimed at collaborating with disruptive technology startups.
The startup has already received nearly $20 million in funding from a number of investors, including Shoni Health Ventures. It was founded in 2020 by Orr Inbar, Arnon Horev and Idan Sugarman
